# A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP3700 in Healthy Subjects

> **NCT02285465** · PHASE1 · WITHDRAWN · sponsor: **Astellas Pharma Europe B.V.**

## Conditions studied

- Healthy Volunteers
- Pharmacokinetics of ASP3700

## Interventions

- **DRUG:** ASP3700
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02285465
- **Lead sponsor:** Astellas Pharma Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-11
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study terminated due to sponsor decision
- **Last updated:** 2015-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02285465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02285465, "A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP3700 in Healthy Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02285465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*